Dr. Robert Figlin on the Increasingly Complicated Treatment Paradigm for Renal Cell Carcinoma
Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.
Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about the increasingly complicated treatment paradigm for renal cell carcinoma (RCC).
Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC. He references a recent study published by The New England Journal of Medicine, where patients with advanced RCC had an improved overall survival rate of 5.4 months while on nivolumab versus everolimus.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
